In a report released on November 1, Thomas Smith from SVB Securities maintained a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $0.90.
According to TipRanks, Smith is an analyst with an average return of -5.1% and a 38.87% success rate. Smith covers the Healthcare sector, focusing on stocks such as Keros Therapeutics, MannKind, and Eledon Pharmaceuticals.
Axcella Health has an analyst consensus of Strong Buy, with a price target consensus of $6.80, implying a 655.56% upside from current levels. In a report released on November 2, Chardan Capital also maintained a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.31 and a one-year low of $1.02. Currently, Axcella Health has an average volume of 160.4K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXLA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
Read More on AXLA:
- Axcella Health reports Q3 EPS (34c), consensus (38c)
- This Insider Bought Axcella Health (NASDAQ:AXLA) Stock Worth $6M
- Roth reiterates $19 target on Axcella after ‘encouraging’ data
- Axcella (NASDAQ:AXLA) Soars on NASH Data; Street Eyes 3.5x Gains
- Axcella Health’s AXA1125 shows efficacy in Phase 2b NASH trial
